About me

Project Manager for the COMMUNITY-study

Coordinator of clinical research agreements at KIDS

Administrator for clinicaltrials.gov

 

Publications:

Marking U, Havervall S, Greilert-Norin N, Ng H, Blom K, Nilsson P, Phillipson M, Hober S, Nilsson C, Mangsbo S, Christ W, Klingström J, Gordon M, Åberg M, Thålin C. Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines. Vaccines. 2022; 10(3):359. 

https://doi.org/10.3390/vaccines10030359

 

Havervall S, Jernbom Falk A, Klingström J, Ng H, Greilert-Norin N, Gabrielsson L, Salomonsson AC, Isaksson E, Rudberg AS, Hellström C, Andersson E, Olofsson J, Skoglund L, Yousef J, Pin E, Christ W, Olausson M, Hedhammar M, Tegel H, Mangsbo S, Phillipson M, Månberg A, Hober S, Nilsson P, Thålin C.PLoS One. 2022 Jan 12;17(1):e0262169. doi: 10.1371/journal.pone.0262169. eCollection 2022

SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection.

 

Havervall S,  Marking U,  Greilert-Norin N,  Ng H,  Gordon M,  Salomonsson AC,  Hellström C,  Pin E,  Blom K,  Mangsbo S,  Phillipson M,  Klingström J,  Hober S,  Nilsson P,  Åberg M,  Thålin C. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2. EBioMedicine 2021 70; 103523-

http://www.ncbi.nlm.nih.gov/pubmed/34391088

 

Havervall S,  Ng H,  Falk AJ,  Greilert-Norin N,  Manberg A,  Marking U,  Lauren I,  Gabrielsson L,  Salomonsson AC,  Aguilera K,  Kihlgren M,  Mansson M,  Rosell A,  Hellstrom C,  Andersson E,  Olofsson J,  Skoglund L,  Yousef J,  Pin E,  Lord M,  Aberg M,  Hedhammar M,  Tegel H,  Donnes P,  Phillipson M,  Nilsson P,  Klingstrom J,  Mangsbo S,  Hober S,  Thalin C. Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19. JOURNAL OF INTERNAL MEDICINE 2021 ;

http://www.ncbi.nlm.nih.gov/pubmed/34459525

 

Effects of Fluoxetine on Outcomes at 12 Months After Acute Stroke: Results From EFFECTS, a Randomized Controlled Trial

Lundström E, Isaksson E, Greilert Norin N, Näsman P, Wester P, Mårtensson B, Norrving B, Wallén H, Borg J, Hankey Gj, Hackett Ml, Mead Ge, Dennis Ms, Sunnerhagen Ks

Stroke 2021;52(10):3082-3087